Presynaptic effects of levodopa and their possible role in dyskinesia.

Levodopa replacement therapy has long provided the most effective treatment for Parkinson's disease (PD). We review how this dopamine (DA) precursor enhances dopaminergic transmission by providing a greater sphere of neurotransmitter influence as a result of the confluence of increased quantal size and decreased DA reuptake, as well as loading DA as a false transmitter into surviving serotonin neuron synaptic vesicles. We further review literature on how presynaptic dysregulation of DA release after l-dopa might trigger dyskinesias in PD patients.
AuthorsEugene V Mosharov, Anders Borgkvist, David Sulzer
JournalMovement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 30 Issue 1 Pg. 45-53 (Jan 2015) ISSN: 1531-8257 [Electronic] United States
PMID25450307 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
Copyright© 2014 International Parkinson and Movement Disorder Society.
Chemical References
  • Dopamine Agents
  • Levodopa
  • Dopamine
  • Animals
  • Dopamine (metabolism)
  • Dopamine Agents (adverse effects)
  • Dyskinesia, Drug-Induced (etiology, metabolism, pathology)
  • Humans
  • Levodopa (adverse effects)
  • Neurons (cytology, drug effects)
  • Parkinson Disease (drug therapy)
  • Presynaptic Terminals (drug effects, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password:
Type Validation Code Shown: